Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006

G. V. Long*, A. Arance, L. Mortier, P. Lorigan, C. Blank, P. Mohr, J. Schachter, J. J. Grob, M. Lotem, M. R. Middleton, B. Neyns, N. Steven, A. Ribas, E. Walpole, M. S. Carlino, C. Lebbe, M. Sznol, E. Jensen, M. A. Leiby, N. IbrahimC. Robert

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Background: Antitumor activity of ipilimumab or BRAF ± MEK inhibitors (BRAFi ± MEKi) following pembrolizumab administration in melanoma is poorly characterized. Patients and methods: In the phase III KEYNOTE-006 study, patients with unresectable stage III/IV melanoma received pembrolizumab (10 mg/kg) once every 2 or 3 weeks (Q3W) or ipilimumab (3 mg/kg) Q3W. The current post hoc analysis evaluates outcomes with ipilimumab or BRAFi ± MEKi as first subsequent systemic therapy after pembrolizumab administration and includes patients who completed or discontinued pembrolizumab after one or more dose. Pembrolizumab arms were pooled. Results: At data cut-off (4 December 2017), median follow-up was 46.9 months. Of 555 pembrolizumab-treated patients, first subsequent therapy was ipilimumab for 103 (18.6%) and BRAFi ± MEKi for 59 (10.6%) [33 received BRAFi + MEKi, 26 BRAFi alone; 37 (62.7%) were BRAFi ± MEKi naïve]. In the subsequent ipilimumab group, ORR with previous pembrolizumab was 17.5% [1 complete response (CR); 17 partial response (PR)]; 79.6% had discontinued pembrolizumab due to progressive disease (PD); median overall survival (OS) was 21.5 months. ORR with subsequent ipilimumab was 15.5%; 11/16 responses (8 CRs; 3 PRs) were ongoing. ORR with subsequent ipilimumab was 9.7% for patients with PD as best response to pembrolizumab. Median OS from ipilimumab initiation was 9.8 months. In the subsequent BRAFi ± MEKi group, ORR with previous pembrolizumab was 13.5% (8 PR); 76.3% had discontinued pembrolizumab due to PD; median OS was 17.9 months. ORR with subsequent BRAFi ± MEKi was 30.5%, 7/18 responses (4 CR, 3 PR) were ongoing. Median OS from BRAFi ± MEKi initiation was 12.9 months. ORR for BRAFi ± MEKi-naïve patients who received subsequent BRAFi ± MEKi was 43.2%; 6/16 were ongoing (3 CR, 3 PR). Conclusions: Ipilimumab and BRAFi ± MEKi have antitumor activity as first subsequent therapy after pembrolizumab in patients with advanced melanoma.

Original languageEnglish
Pages (from-to)204-215
Number of pages12
JournalAnnals of Oncology
Volume33
Issue number2
DOIs
StatePublished - Feb 2022
Externally publishedYes

Funding

FundersFunder number
Aduro Biotech Inc
Agilent and Bristol Myers Squibb
Board for Avantis Medical Systems
Evaxion Biotech A/S, Hexal AG
Highlight Therapeutics S.L. Novartis Pharma AG
ImaginAb
Medison
OncoHost
OncoSec
Pierre-Fabre
QBiotics Group Limited
SkylineDx B.V. Specialised Therapeutics Australia Pty Ltd
AMGEN
Bristol-Myers Squibb
Eli Lilly and Company
Pfizer
AstraZeneca
GlaxoSmithKline
Johnson and Johnson
Merck
Novartis
Roche
Sanofi
Regeneron Pharmaceuticals
Merck Sharp and Dohme
Les Laboratories Pierre Fabre
TG Therapeutics
European Commission
Mount Sylvia Diatomite

    Keywords

    • BRAF inhibition
    • MEK inhibition
    • advanced melanoma
    • ipilimumab
    • pembrolizumab

    Fingerprint

    Dive into the research topics of 'Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006'. Together they form a unique fingerprint.

    Cite this